Industry News Sponsored by
Evolva Holding SA’s 2013 total revenue rose to CHF 8.7 million compared with CHF 7 million in 2012 it narrowed its operational loss to CHF 17.7 million from CHF 20 million a year earlier.
The company said it’s seeing good progress on its different projects: Evolva’s vanillin pre-production phase completed successfully with a commercial launch imminent. It said Resveratrol is on track for a launch in the second half of 2014 and Stevia is on track for launch in 2015 or 2016, with announcements expected during the course of 2014 that validate this projection. Saffron is on track for launch in 2016.
Evolva also expects to announce additional partnerships in 2014 with respect to Evolva’s technology and products.